The non-profit Institute for Clinical and Economic Review
has posted for comment their updated
Value Assessment Framework. ICER is an independent research
institute that analyzes evidence on the effectiveness and value of drugs
and other treatments, including evidence-based calculations of prices for new
drugs that accurately reflect their value in long-term patient outcomes and
highlighting prices that may be unaffordable for the entire health system. ICER’s
assessments have been essential to government and private payers in
assessing the value of new drugs and other treatments and keeping health care
affordable. The new improvements to the framework have earned
positive feedback. It builds on ICER’s work over the last two years with
stakeholders to improve transparency and reflects input from over 50 patient
groups, life science companies, insurers and policymakers. Improvements include
emphasis on patient-reported outcomes, expanded standards for
cost-effectiveness ratios, and use of real, rather than list, prices that take
account of rebates.
